Fragile X Drug Developer SAGE Therapeutics Names New Chief Executive
New SAGE Therapeutics chief executive Jeffrey Jonas will oversee the company’s drug development program for Fragile X syndrome, which last month received a grant worth up to $10 million from the National Institutes of Health.